Page 22 - Portuguese Journal - SPORL - Vol 61. Nº2

Figure 7 Table 1
Loss of smell score (LSS) and The 40-item Nasal congestion score (NCS)
University of Pennsylvania Smell Identification
Test (UPSIT).

Criteria for inclusion for treatment with
biologics
• Age ≥ 18 years.
• CRS with bilateral sinonasal polyposis in a
patient who has previously undergone ESS
or with a surgical contraindication and at
least three of the following criteria:
• Evidence of type 2 inflammation: tissue
eosinophilia ≥ 10 eosinophils/high-power
field or peripheral eosinophilia ≥ 250 or
total IgE ≥ 100
• Assess peripheral eosinophilia and/or
total IgE if treatment with biologics is
considered
• In patients who underwent ESS and
suspected type 2 inflammation, assess
tissue eosinophilia (data on the disease
assesses the severity of symptoms and endotype remains in case treatment
social and emotional problems related to with biologics is needed)
the condition. The score ranges from 0 (no • Need for systemic corticosteroids (≥ 2
interference) to 110 (maximum interference courses/year or for more than 3 months) or
with the quality of life), and the minimal systemic corticosteroids contraindicated
clinically important difference (MCID) is 8.9 • Significantly compromised quality of life
points . The questionnaire that has been (SNOT-22 score ≥ 40 points)
30
validated in Portuguese in Portugal is shown • Anosmia in smell assessment (LSS)
31
in Table 2. • Diagnosis of asthma (asthma requiring
regular inhaled corticosteroids)
Total symptom Visual Analog Scale (VAS)
This scale assesses the patient’s perception
of the severity of all rhinosinusitis symptoms
in the last month by drawing a vertical line
in a 10-cm scale (0 – minimum up to 10 –
32
maximum (Table 3).

164 Portuguese Journal of Otorhinolaryngology - Head and Neck Surgery